Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
Recruiting
The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: * How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment? * How do risk markers of disease change over the study in the study participant... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/01/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Obesity and Overweight, Obese Adolescents, Weight Management, Weight Loss, Cardiovascular Disease Risk Factor